Evidence map›Paper›PMID 41551852›Full record

ArticleCell reports. Physical science2025

A zirconium-89-labeled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin4 expression in breast cancer and lung cancer.

Wenpeng Huang, Tianyao Wang, Yutong Liang, Fangfang Chao, Qi Yang, Todd E Barnhart, Jonathan W Engle, Liming Li, Lei Kang, Weibo Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Physical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenpeng HuangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Tianyao WangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Yutong LiangMichigan State University College of Osteopathic Medicine, East Lansing, MI 48824, USA.
Fangfang ChaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Qi YangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Todd E BarnhartDepartments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA.
Jonathan W EngleDepartments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA.
Liming LiDepartment of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Lei KangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Weibo CaiDepartments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are aggressive solid tumors with limited treatment options. Nectin cell adhesion molecule 4 (Nectin4) is a tumor-associated antigen frequently overexpressed in these cancers, making it a promising therapeutic and imaging target. Here, we report the development and evaluation of [

Identifiers

PMID41551852
PMCPMC12806174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.